Atrial Fibrillation | Disease Landscape & Forecast | G7 | 2024
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF is the most common arrhythmia treated in clinical practice. Pharmacological treatment includes rate control therapy (e.g., beta blockers, calcium channel blockers, digoxin) and anticoagulation therapy (e.g., vitamin K antagonists, direct-acting oral anticoagulants [DOACs]). Novel agents being investigated in clinical trials to treat AF include Anthos Therapeutics’ abelacimab and BMS / Johnson & Johnson Innovative Medicine’s milvexian. We expect these drugs to launch during the forecast period and to fulfill some of the unmet needs that remain in AF.
Questions answered
- What do key opinion leaders think about emerging therapies such as abelacimab and milvexian? How will emerging therapies differentiate themselves in an increasingly crowded market?
- What are the key treatment drivers and goals within AF? How do current therapies perform on these goals?
- What are the key unmet needs in AF, and how likely are they to be met?
Geography: United States, France, Germany, Italy, Spain, United Kingdom, and Japan
Primary research: 17 country-specific interviews with thought-leading cardiologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total prevalent cases of AF by country, diagnosed and undiagnosed; paroxysmal, persistent, and permanent diagnosed prevalent cases.
Forecast: 10-year, annualized, drug-level sales and patient share of key AF therapies through 2033, segmented by brands/generics as well as paroxysmal, persistent, and permanent diagnosed prevalent cases.
Drug treatments: Coverage of key current and emerging therapies.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
